Flynn Helps Launch New Colon Cancer Screening Test

ROCHESTER, N.Y., March 22, 2024 – Integrated marketing agency Flynn today announced its newest client, Cleveland-based Reese Pharmaceutical Company. Flynn will help launch Reese’s ColoTest, a new FDA-cleared over-the-counter Fecal Immunochemical Test (FIT) designed to screen for blood in the stool.

Reese selected Flynn for the agency’s deep experience launching and growing challenger OTC brands, as well as its proven track record acquiring new patients in the diagnostics and consumer-initiated testing space—including three years spent scaling Quest Diagnostics’ direct-to-consumer channel to 14X revenue.

ColoTest offers consumers a more accessible, affordable way to monitor for a key warning sign of colon health issues such as colon cancer, diverticulitis, colitis, and polyps. Available without a doctor’s prescription, the test can be performed at home with 98.8% accurate results as soon as one minute after use.

“Consumers are taking charge of their own health more and more, especially via at-home monitoring and preventative care,” said Heather Riexinger, Account Director at Flynn. “We’re thrilled to champion a product that helps people detect an early warning sign of colon cancer without paying sky high prices for similar FIT tests, and without waiting for a prescription or insurance to take action.”

Flynn will develop the creative and media strategy for the ColoTest launch, growing awareness of the new product and driving purchases in retail stores and online. ColoTest is now available on shelves in Walmart stores nationwide, debuting during Colorectal Cancer Awareness Month.

“Colon cancer is the third-most common cancer in the US and the second most deadly,” said Jeff Reese, President at Reese Pharmaceutical. “With the rollout of ColoTest, there is no reason why those at risk or who can’t afford a colonoscopy should wait to screen themselves.”